Enanta Pharmaceuticals
ENTA
154 hedge funds and large institutions have $856M invested in Enanta Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 55 increasing their positions, 59 reducing their positions, and 21 closing their positions.
1,057% more call options, than puts
Call options by funds: $7.16M | Put options by funds: $619K
1.87% more ownership
Funds ownership: 95.82% → 97.69% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 59
9% less funds holding
Funds holding: 169 → 154 (-15)
39% less capital invested
Capital invested by funds: $1.4B → $856M (-$544M)
52% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 21
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$51.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$8.55M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.04M |
| 5 |
JP Morgan Chase
New York
|
+$7.49M |
Top Sellers
| 1 |
First Manhattan
New York
|
-$30.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$14.1M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$8.54M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.56M |
| 5 |
Walleye Capital
New York
|
-$4.49M |
ENTA Hedge Fund Activity: Q2 2022 in Review
154 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2022, worth a combined $856M — down 39% from $1.4B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ENTA and 10 opened new positions — a net loss of 11 holders — while 59 trimmed existing stakes and 55 added.
The largest buyer was Armistice Capital, adding an estimated $51.3M. The largest seller was First Manhattan, cutting an estimated $30.5M.
- 154 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2022, down from 169 in Q1 2022.
- Funds reported $856M of Enanta Pharmaceuticals stock for Q2 2022, down 39% quarter-over-quarter.
- 10 funds opened new Enanta Pharmaceuticals positions in Q2 2022 and 21 closed out, a net change of -11 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2022 was Armistice Capital, an estimated $51.3M added.
- The largest Enanta Pharmaceuticals seller in Q2 2022 was First Manhattan, an estimated $30.5M sold.
Based on aggregated 13F filings for Q2 2022.